Here is the short answer. UpToDate remains a curated, editorially controlled reference that most hospitals already license, and its generative layer, UpToDate Expert AI, answers only from that curated corpus. OpenEvidence is a free, advertising funded search tool for NPI verified US clinicians that answers from the primary literature with inline citations, and it has spread faster than any clinical reference product in memory. Deciding between them in the UpToDate vs OpenEvidence debate is less about which one is smarter and more about which failure mode you can live with at 2 a.m.
That framing matters now because 2026 gave us the first real independent data on both, and the results were not what anyone expected. If you want the wider category view first, start with our guide to point of care tools in 2026 and come back here for the head to head.
The adoption gap is not subtle
OpenEvidence told NBC News it was used by roughly 65% of US doctors across almost 27 million clinical encounters in April 2026 alone, with about 650,000 active US physicians and another 1.2 million users internationally [1]. In January 2026 the company raised $250 million at a $12 billion valuation, and its CEO said the platform had passed $100 million in annual revenue [2]. Consultation volume ran near 18 million per month in December 2025, across more than 10,000 hospitals and medical centers [3].
UpToDate is not small. Wolters Kluwer reports more than 3 million clinician users, content built by over 7,600 physician authors, editors, and peer reviewers, and 30 years of institutional trust that shows up in hospital protocols and privileging conversations [4]. Its generative product, UpToDate Expert AI, launched in September 2025, and by the end of April 2026 more than half of US Enterprise Edition customers, roughly 2,000 hospitals, had signed on to adopt it [5].
None of this is happening in a vacuum. The AMA's 2026 Physician Survey on Augmented Intelligence found that 81% of physicians now use AI in a professional context, double the 38% reported in 2023, with medical research summarization the single most common use case at 39% [6]. So the question is no longer whether your colleagues are using these tools. They are. The question is what the tools are actually good at.
UpToDate vs OpenEvidence: what the head to head evidence shows
In June 2026, a group at NYU Langone published the first independent head to head evaluation of both products in Nature Medicine. They tested OpenEvidence and UpToDate Expert AI against three general purpose frontier models across 500 MedQA questions, 500 HealthBench items, and a benchmark of 100 de-identified real clinical queries pulled from physicians working in a live clinical environment, with 12 US clinicians producing 1,800 blinded annotations [7].
The frontier models won all three stages. On MedQA, Gemini 3.1 Pro scored 97.4% against 89.6% for OpenEvidence and 88.4% for UpToDate. On HealthBench, GPT-5.2 scored 88.0 against 62.6 and 61.3. On the real query benchmark, the clinical tools performed no better than Google's auto-enabled Search AI Overview, and UpToDate Expert AI declined to answer 19% of the queries, more than any other system tested [7], [8].
OpenEvidence rejected the finding. In a June 15 letter obtained by Becker's, the company asked Nature Medicine to retract the paper, arguing the public benchmarks may have leaked into the frontier models' training data. The study authors had already acknowledged that contamination risk, which is exactly why they designated the real clinical query benchmark, the one free of that problem, as their primary evidence. The frontier models led there too, and the senior author said publicly that the team stands by the work [8].
Twelve days later, a competing evaluation landed on arXiv with the opposite result. Feng and colleagues built a benchmark of 620 real point of care questions drawn from the OpenEvidence platform, then had 149 practicing physicians across 36 states, matched to each question by specialty, compare blinded answers head to head. OpenEvidence beat all three frontier models on every axis, including a 24.7 percentage point win difference on accuracy and 38.8 points on source quality [9].
Before you pick a side, read the methods. OpenEvidence co-developed the data collection plan, ran the survey, and paid the respondents, although the authors are unaffiliated with the company and the statistical plan was pre-specified and blinded [9]. The questions came from OpenEvidence's own platform, which shapes the distribution toward the questions physicians already route to that tool. The Nature Medicine questions came from an enterprise ChatGPT instance, which shapes it the other way.
Both studies are probably measuring something real. Tools tuned for a specific query distribution win on that distribution. That is the honest takeaway, and it is more useful than a ranking.
The subspecialty ceiling nobody advertises
OpenEvidence announced in August 2025 that it scored 100% on USMLE style questions [10]. Board style multiple choice is not the same as subspecialty reasoning.
A pilot study posted to medRxiv in December 2025 ran 100 subspecialty scenarios from the MedXpertQA dataset through both OpenEvidence modes, scored by two independent evaluators. Quick Consult averaged 31% accuracy. Deep Consult averaged 39.5%. Same answer repeatability between evaluators was 77% and 72% respectively. Deep Consult took a median of 240 seconds and returned a median of 33 references, against 13 seconds and 5 references for the quick search [11].
The line from that paper that should stay with you: neither mode ever said it did not know the answer [11].
Two earlier studies point the same direction. Hurt and colleagues found that in five common primary care conditions, OpenEvidence scored well on clarity and relevance but rarely changed the plan, meaning it mostly reinforced what the physician already intended to do [12]. Low and colleagues, comparing systems on 50 open ended clinical scenarios rated by nine physicians, found wide performance gaps across tools [13]. Reinforcement feels like validation. It is not the same as decision support.
Comparison table
One thing the table cannot capture: these are all reference tools. They answer questions. They do not sit in the encounter and listen, which is a different product category with a different risk profile, covered in our breakdown of ambient AI scribes versus clinical copilots.
Try this before you switch anything: run your last five real clinical questions through both tools and grade the answers yourself against the primary source. Physicians' Copilot Clinical AI is built for exactly that kind of side by side check, so you can see how the answers differ on your questions rather than someone else's benchmark. See how Physicians' Copilot compares.
Free is a business model, not a gift
OpenEvidence is free because pharmaceutical and medical device companies pay to reach you while the answer loads [1]. That model is not disqualifying, and it is the same economic engine that has funded medical media for decades. It does deserve to be named out loud, because the point of exposure sits closer to the prescribing decision than a journal ad ever did.
UpToDate has historically funded itself through subscriptions rather than advertising, which is a genuine structural difference. It is also the reason it costs money. Wolters Kluwer does not publish individual pricing on its marketing pages, and the webstore requires you to select country and professional role before showing a rate. Secondary sources report figures in the range of roughly $500 to $700 per year for a personal professional subscription, but those figures trace back to vendor blogs rather than a primary source, so treat them as an estimate and confirm at store.uptodate.com.
One detail worth knowing if you are a resident or fellow: subscriptions purchased at the trainee rate do not carry CME eligibility [17].
What ECRI actually said
You have probably seen the headline that AI chatbots topped ECRI's 2026 list of health technology hazards, above cyberattacks and device recalls [18]. It is being quoted in vendor marketing in a way that misrepresents it.
ECRI tested commonly available general purpose chatbots, naming ChatGPT, Claude, Copilot, Gemini, and Grok. It deliberately excluded purpose built clinical applications, including OpenEvidence, from the analysis [19]. The hazard ECRI described is clinicians and patients treating an unvalidated general assistant as a clinical reference, not the existence of clinical AI.
The recommendations are still worth following, and they apply to every tool in this article: know the limitations, verify anything consequential against a primary source, and keep a human in the loop [18].
How to use either one without getting burned
Match the tool to the question. Retrieval questions ("what did the 2025 guideline change") suit OpenEvidence. Orientation questions ("walk me through the workup") suit a UpToDate topic. Reasoning through a messy multi-problem patient is where a frontier model tends to do well, and where you must verify everything.
Ask better questions. Answer quality tracks question specificity more than most physicians expect, and the habits that help are learnable. We cover them in how to get reliable clinical answers from AI.
Open the citation. An accurate citation attached to a mistaken interpretation is the most common failure mode across these systems, and it is invisible if you only read the summary.
Watch for confident silence. Neither OpenEvidence mode in the medRxiv pilot ever declined to answer [11]. UpToDate Expert AI declines often, refusing 19% of real queries in the Nature Medicine evaluation [7], [8]. Both behaviors mislead in different directions.
Keep PHI out unless your institution has signed for it. Enterprise deployments and consumer accounts are not the same thing, and your compliance office is the authority here, not a marketing page.
Do not let it replace the reasoning rep. In the AMA survey, 88% of physicians reported concern about skill loss, and the concern was sharpest among those with ten years or less in practice [6]. That worry is well placed if the tool routinely confirms what you already thought.
Check who paid for the benchmark. This applies to every accuracy claim in this space, including the two studies above.
Regulators have not settled this either. FDA published a revised clinical decision support guidance on January 6, 2026, superseding the 2022 version. The agency's focus remains on whether the clinician can understand the basis of a recommendation, regardless of whether it came from AI [20]. That standard puts the burden back on you.
What I would tell a colleague
Most physicians I know are not choosing. They keep institutional UpToDate for depth and defensibility, they use OpenEvidence for speed, and a growing number quietly check a frontier model when a case will not resolve. The 2026 evidence supports that hedging more than it supports loyalty to any single product.
The tools are converging in features. UpToDate added CME inside its AI workflow in March 2026 [14], and OpenEvidence launched accredited CE and MOC in July 2026 [15]. What is not converging is verification discipline, and that stays your job.
Physicians' Copilot exists because the answer is only half the work. Our Clinical AI shows the evidence path alongside the answer so you can audit it in seconds, and it sits next to the compensation and job tools you already use. See how Physicians' Copilot compares.
No AI tool replaces clinical judgment. Verify all outputs against primary sources and your own assessment.
Key takeaways
OpenEvidence reached roughly 65% of US physicians and nearly 27 million encounters in April 2026, but scale is an adoption signal, not an accuracy signal [1].
The independent Nature Medicine evaluation found both OpenEvidence and UpToDate Expert AI trailing general purpose frontier models, performing no better than Google's AI Overview on real physician queries [7].
A company supported evaluation using OpenEvidence's own query distribution found the opposite, which tells you how much benchmark design drives the result [9].
On subspecialty board style scenarios, OpenEvidence accuracy averaged 31% for quick search and 39.5% for Deep Consult, and neither mode ever declined to answer [11].
Free means advertising funded. Paid means subscription funded. Both models carry incentives worth naming before you decide.
REFERENCES
All URLs accessed August 22, 2026.
NBC News. "Most U.S. doctors are quietly using this AI tool." Published May 13, 2026. https://www.nbcnews.com/tech/tech-news/openevidence-ai-doctor-medical-physician-login-app-what-npi-uptodate-rcna341064
CNBC. "OpenEvidence, the 'ChatGPT for doctors,' doubles valuation to $12 billion." Published January 21, 2026. https://www.cnbc.com/2026/01/21/openevidence-chatgpt-for-doctors-doubles-valuation-to-12-billion.html
Fierce Healthcare. "OpenEvidence clinches $250M in series D, rapidly growing its reach with doctors." Published January 21, 2026. https://www.fiercehealthcare.com/ai-and-machine-learning/openevidence-clinches-250m-series-d-rapidly-growing-its-reach-doctors
Fierce Healthcare. "Wolters Kluwer jumps into the AI market, rolls out gen AI version of UpToDate." Published October 6, 2025. https://www.fiercehealthcare.com/ai-and-machine-learning/wolters-kluwer-rolls-out-gen-ai-version-uptodate-clinical-decision-support
Wolters Kluwer. "Wolters Kluwer and OpenAI expand enterprise AI collaboration to advance trusted Expert AI for regulated professionals." Published June 2026. https://www.wolterskluwer.com/en/news/wolters-kluwer-and-openai-expand-enterprise-ai-collaboration-to-advance-trusted-expert-ai
American Medical Association. "AMA: AI usage among doctors doubles as confidence in technology grows" and 2026 Physician Survey on Augmented Intelligence. Published March 12, 2026. https://www.ama-assn.org/press-center/ama-press-releases/ama-ai-usage-among-doctors-doubles-confidence-technology-grows
Vishwanath K, Alyakin A, Ghosh M, et al. "General-purpose large language models outperform specialized clinical AI tools on medical benchmarks." Nature Medicine. 2026;32:2405-2409. Published June 12, 2026. https://www.nature.com/articles/s41591-026-04431-5
Becker's Hospital Review. "ChatGPT, Gemini, Claude outperform clinical AI tools: Study." Published June 17, 2026. https://www.beckershospitalreview.com/healthcare-information-technology/ai/chatgpt-gemini-claude-beat-clinical-ai-tools-study/
Feng J, Patel V, Heagerty P, et al. "Expert Evaluation of Clinical AI Tools on Real Point-of-Care Clinical Queries." arXiv preprint 2606.28960. Posted June 27, 2026. https://arxiv.org/abs/2606.28960
OpenEvidence. "OpenEvidence creates the first AI in history to score a perfect 100% on the United States Medical Licensing Examination (USMLE)." Published August 15, 2025. https://www.openevidence.com/announcements/openevidence-creates-the-first-ai-in-history-to-score-a-perfect-100percent-on-the-united-states-medical-licensing-examination-usmle
Jagarapu J, Babata K, Chamarthi S, Hoyt R. "The accuracy and repeatability of OpenEvidence on complex medical subspecialty scenarios: a pilot study." medRxiv preprint. Posted December 4, 2025. https://www.medrxiv.org/content/10.64898/2025.11.29.25341091v1
Hurt RT, Stephenson CR, Gilman EA, et al. "The use of an artificial intelligence platform, OpenEvidence, to augment clinical decision-making for primary care physicians." J Prim Care Community Health. 2025;16:21501319251332215. https://pubmed.ncbi.nlm.nih.gov/40238861/
Low YS, Jackson ML, Hyde RJ, et al. "Answering real-world clinical questions using large language models, retrieval-augmented generation, and agentic systems." Digit Health. 2025;11:20552076251348850. https://pubmed.ncbi.nlm.nih.gov/40510193/
Wolters Kluwer. "Wolters Kluwer UpToDate Expert AI now awards Continuing Medical Education (CME) Credits." Published March 18, 2026. https://www.wolterskluwer.com/en/news/wolters-kluwer-uptodate-expert-ai-now-awards-continuing-medical-education-cme-credits
OpenEvidence. "OpenEvidence launches new education platform offering Continuing Education (CE) and Maintenance of Certification (MOC) credit." Published July 28, 2026. https://www.openevidence.com/announcements/openevidence-launches-new-education-platform-offering-continuing-education-ce-and-maintenance-of-certification-moc-credit
Wolters Kluwer. "UpToDate Pro Plus: AI-powered clinical decision support for medical professionals." Product page, accessed August 22, 2026. https://www.wolterskluwer.com/en/solutions/uptodate/pro/uptodate/uptodate-pro-plus
American Academy of Family Physicians. "UpToDate subscription discounts." Member benefit page, accessed August 22, 2026. https://www.aafp.org/membership/benefits/advantage/uptodate.html
ECRI. "Misuse of AI chatbots tops annual list of health technology hazards." Published January 21, 2026. https://home.ecri.org/blogs/ecri-news/misuse-of-ai-chatbots-tops-annual-list-of-health-technology-hazards
Betsy Lehman Center for Patient Safety. "AI chatbots top ECRI's list of health technology hazards for 2026." Published February 2026. https://betsylehmancenterma.gov/news/normalization-of-ai-chatbots-presents-risks-and-benefits-in-health-care-or-ai-chatbots-top-ecris-list-of-technology-hazards-for-2026
Arnold & Porter. "FDA 'cuts red tape' on clinical decision support software and wearable products for general wellness." Published January 21, 2026. https://www.arnoldporter.com/en/perspectives/advisories/2026/01/fda-cuts-red-tape-on-clinical-decision-support-software
FAQs
On the benchmarks published so far they land in the same tier, with OpenEvidence slightly ahead on MedQA (89.6% against 88.4%) and marginally ahead on HealthBench, while both trailed frontier general models [7], [8]. Accuracy also varies sharply by question difficulty. On subspecialty scenarios, OpenEvidence performance dropped well below 50% [11]. Neither tool has published independent evidence that it changes patient outcomes.